[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@hhashmi87 Hamza Hashmi
Hamza Hashmi posts on X about events, 12m, rx, tec the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX +2,000%
- X Month XXXXX +2,038%
- X Months XXXXXX +1,153%
- X Year XXXXXX +124%
Mentions: X #
Followers: XXX #
- X Week XXX +5.30%
- X Month XXX +7.90%
- X Months XXX +23%
- X Year XXX +30%
CreatorRank: XXXXXXXXX #
Social Influence
Social topic influence events, 12m, rx, tec, ab, $fro, immune, stem, future, we will
Top accounts mentioned or mentioned by @rahulbanerjeemd @ashhematology @hadidisamer @szusmani @gkaurmd @mskcancercenter @bdermanmd @myelomadoc @vincentrk @endmyeloma @joshuarichtermd @andrew02114 @omarnadeemmd @drolalandgren @jkaufmanmd @drkrinapatel @urvishahmd @rossfirestone @kordeneha1 @sridevirajeeve
Top assets mentioned Frontline Ltd. (FRO)
Top Social Posts
Top posts by engagements in the last XX hours
"Presented at #IMS25 now in @BloodPortfolio 👉22% of NDMM HR by new IMWG Consensus Genomic model 👉CD38 Ab & ASCT had PFS for both SR and HR 👉If no HR genomics B2M had similar outcomes as normal B2M #MMSM #MedTwitter @ASchavgoulidze 👏👏"
X Link 2025-09-30T13:34Z XXX followers, 4253 engagements
"Oral Abstract 0697: @Myeloma_Doc showing LINKER-MM4 data on linvo in NDMM: despite high disease burden grade X CRS XX% G3 infection XX% in first 3m early & deep responses MRD neg (100%). Rates of infection remain as frontline Rx all pts on BsAb should get IVIG #ASH25 #MMSM"
X Link 2025-12-07T21:42Z XXX followers, XXX engagements
"Oral abstract 0699: Adam Cohen on Cevo x6m as post BCMA CAR T consolidation to achieve MRD negativityn=27 mostly cilta-cel all pts MRD neg before Cevo. Unusual immune AE seen. Should look into ide-cel pts & those who are MRD+ at D30 and with high risk dx EMD #ASH25 #MMSM"
X Link 2025-12-07T22:15Z XXX followers, XXX engagements
"3) Efficacy: Tec-Dara vs DPD/DVD ➡3 yr PFS XX% vs XX% (HR=.17) ➡3yr OS XX% vs XX% (HR=0.46) ➡Better CR (80% vs 30%) & MRD neg 10-5 XX% vs XX% 💡Some early PFS events w Tec Dara w all those who sustained responses 12m relapse free and alive at 36m #FlattenTheCurve 💡15% RRMM remain ultra-high risk and declare themselves 6m #UnMetNeed"
X Link 2025-12-09T14:00Z XXX followers, XXX engagements
"This is one of the largest RWE for stem cell boost for post CAR T cytopenias being presented at #ASH25 pts w severe refractory cytopenias recovered counts quickly and effectively with previously stored stem cells"
X Link 2025-12-04T19:49Z XXX followers, XXX engagements
"5) Take home Message: đź’ˇTec Dara as effective as CAR T as 2L Rx (3yr PFS for SR in CART-4 80%) đź’ˇNo risk of NINT and enterocolitis đź’ˇRisk of BCMA loss/ mutations & T-cell exhaustion đź’ˇNeed for ongoing Rx risk of infections need for IVIG đź’°đź’°đź’° đź’ˇNeeds to be time limited Rx guided by MRD neg (12m) to address these issues #LimiTEC đź’ˇIdeal pt: relapse on Len maintenance not ideal for Ciltacel (old frail cognitive or caregiver or access issues)âś… for CD38 for those progressing on monthly Dara đź’ˇPrefer CART in those high risk (15%) progressing 6m on Tec-Dara in trial đź’ˇWhile BsAb are easy for"
X Link 2025-12-09T14:00Z XXX followers, XXX engagements
"6) Future directions: đź’ˇTime to MRD negativity w Tec Dara and cessation of Rx (12m) đź’ˇRWE for Dara exposed & Ref pts receiving Tec and Dara as 2L đź’ˇBCMA loss/mutations in the early progressors on Tec Dara; Is CAR T still going to work đź’ˇEducate community providers to continue to refer pts at first relapse to discuss all options đź’ˇUnclear how long we will debate CAR T vs Tec Dara as 2L as Tec (MAJ-7) and CAR T (MAJ-5 CAR T-6) will likely make it to first line"
X Link 2025-12-09T14:00Z XXX followers, XXX engagements
"Oral Abstract: @Marivimateos: 3yr F/u of Tec+Talq for RRMM ORR XX% CR XX% X yr PFS XX% G3 infection XX% hypogamma XX% infection risk w time but remains significant. More pts w EMD penta refractory prior BCMA Rx than CAR T-1. CART is still one & done. #ASH25 #MMSM"
X Link 2025-12-07T22:45Z XXX followers, XXX engagements
"4) Adverse events: ➡CRS XX% (no prophy Toci allowed) mostly G1 ICANS X% ➡G3 infection XX% vs XX% (IVIG encouraged but only mandated after 2/2023) ➡MM related symptoms over time due to disease control 💡Infection rates decreased w Q4 dosing mandated IVIG use and better myeloma control #IVIGforAll 💡Initial cross over of OS curves due to infection related deaths 💡Imp to look at PRO data and see if decline beyond 12m Rx due to ongoing Rx"
X Link 2025-12-09T14:00Z XXX followers, XXX engagements
"@rajshekharucms IMO time limited Rx should be guided by time to MRD negativity data in the trial. XX% achieved MRD neg by 10-6 (evaluable dataset) vast majority sustained at 6m. I would suggest stopping Rx at 12m if MRD neg. No drop in the PFS curve beyond 12m #MMSM #ASH25"
X Link 2025-12-09T16:47Z XXX followers, 3233 engagements